CLEVELAND - Sotera Health Company (NASDAQ:SHC), a global provider of sterilization solutions and lab services, announced the pricing of its secondary stock offering at $14.75 per share. The offering consists of 25 million shares sold by existing stockholders, including affiliates of private equity firms Warburg Pincus LLC and GTCR LLC, two management members, and one board director.
The underwriters, led by J.P. Morgan, Goldman Sachs & Co (NYSE:GS). LLC, Citigroup, and Jefferies, have the option to purchase up to an additional 3.75 million shares. The transaction is expected to close on March 4, 2024, subject to standard closing conditions.
Sotera Health will not sell any new shares nor will it receive proceeds from the offering, but it will cover certain related expenses. The offering is being conducted through a prospectus, obtainable from the aforementioned financial institutions.
This secondary offering comes after the company's registration statement filed with the SEC became effective on February 27, 2024. The sale of these securities is restricted in certain jurisdictions until all local securities laws are complied with.
The press release includes forward-looking statements subject to risks and uncertainties detailed in the company's SEC filings, including its most recent Form 10-K. Sotera Health emphasizes its commitment to safeguarding global health through its Sterigenics®, Nordion®, and Nelson Labs® businesses.
The information regarding the secondary offering is based on a press release statement from Sotera Health Company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.